News

MRI-Adapted M-RECIST Better Characterizes Treatment Response After Cryoablation in Desmoid-Type Fibromatosis

09/14/2026

Emily Estrada

MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...

MRI-adapted M-RECIST identified...

09/14/2026

Oncology

News

Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors

08/31/2026

Emily Estrada

A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...

A real-world study of...

08/31/2026

Oncology

News

Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors

07/28/2026

Emily Estrada

A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...

A real-world study found that...

07/28/2026

Oncology

News

Real-World Study Highlights Evolving Treatment Patterns and Persistent Diagnostic Challenges in Patients With Desmoid Tumors

07/28/2026

Emily Estrada

Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...

Real-world findings demonstrated...

07/28/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology

News

Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Progressive Desmoid Tumors

07/06/2026

Emily Estrada

Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...

Results from a phase 3 trial...

07/06/2026

Oncology

News

M-RECIST Improves Response Assessment Following Cryoablation in Extra-Abdominal Desmoid-Type Fibromatosis

07/06/2026

Emily Estrada

Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...

Results from a retrospective...

07/06/2026

Oncology

News

Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.

Results from the phase 3...

06/08/2026

Oncology

News

Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.

Results from the phase 3...

06/08/2026

Oncology

News

Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.

Results from a retrospective...

06/08/2026

Oncology

Recent News

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology

News

Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

09/15/2026

Emily Estrada

Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...

Topline results from the phase 3...

09/15/2026

Oncology